Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

Literature DB >> 30190868

Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

Upendra P Hegde^1,2,1,2, Bijay Mukherji^1,1, Jane M Grant-Kels^1,1.

Abstract

Entities: Disease Species

Keywords: T cells; aging; anti-CTLA-4; anti-PD-1; effector T cells; elderly; immune checkpoint inhibitor; immunosenescence; immunotherapy; metastatic melanoma; regulatory T cells

Year: 2016 PMID： 30190868 PMCID： PMC6094635 DOI： 10.2217/mmt.15.39

Source DB: PubMed Journal: Melanoma Manag ISSN： 2045-0885

× No keyword cloud information.

16 in total

1. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

2. Spontaneous regression of primary malignant melanomas with regional metastases.

Authors: J L Smith; J S Stehlin
Journal: Cancer Date: 1965-11 Impact factor: 6.860

Review 3. Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors: Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544

Review 4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors: M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544

Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

1. Improved survival with ipilimumab in patients with metastatic melanoma.

2. Spontaneous regression of primary malignant melanomas with regional metastases.

Review 3. Management of immune-related adverse events and kinetics of response with ipilimumab.

Review 4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Review 5. Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

6. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.

Review 7. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Review 8. Melanoma in the elderly patient: relevance of the aging immune system.

9. Cancer immunotherapy: moving beyond current vaccines.

10. Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.

1. Age-related transcriptome changes in melanoma patients with tumor-positive sentinel lymph nodes.